Q1 Earnings Forecast for Neurogene Issued By Leerink Partnrs

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Neurogene in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($1.12) per share for the quarter. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Leerink Partnrs also issued estimates for Neurogene’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($4.76) EPS and FY2026 earnings at ($6.03) EPS.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.05. The firm had revenue of $0.93 million for the quarter.

NGNE has been the subject of a number of other research reports. William Blair reaffirmed an “outperform” rating on shares of Neurogene in a research report on Tuesday. HC Wainwright lowered their target price on Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $59.80.

Neurogene Price Performance

NGNE stock opened at $14.52 on Thursday. The firm has a fifty day moving average price of $16.88 and a two-hundred day moving average price of $28.82. Neurogene has a 1-year low of $13.47 and a 1-year high of $74.49. The firm has a market cap of $215.69 million, a price-to-earnings ratio of -3.40 and a beta of 1.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC raised its stake in shares of Neurogene by 319.4% during the third quarter. Barclays PLC now owns 14,859 shares of the company’s stock valued at $623,000 after purchasing an additional 11,316 shares in the last quarter. FMR LLC increased its stake in Neurogene by 912.4% during the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after buying an additional 659,515 shares during the period. Franklin Resources Inc. bought a new stake in shares of Neurogene during the 3rd quarter worth about $296,000. State Street Corp lifted its stake in shares of Neurogene by 17.5% in the 3rd quarter. State Street Corp now owns 246,540 shares of the company’s stock worth $10,345,000 after acquiring an additional 36,687 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Neurogene in the third quarter valued at approximately $324,000. Institutional investors own 52.37% of the company’s stock.

Insider Activity at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the sale, the chief financial officer now directly owns 72,343 shares in the company, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.92% of the stock is currently owned by insiders.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.